Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumours

Q J Nucl Med. 2000 Mar;44(1):42-9.


Background: Somatostatin receptor imaging with 111In-pentetreotide is widely accepted as an essential step in the management of patients affected by neuroendocrine tumours of the gastro-entero-pancreatic tract. Many data are already available on the high sensitivity of this technique.

Methods: We present a review of the published data together with the results of a study involving 253 patients submitted to somatostatin receptor imaging in three Italian hospitals. The patients were divided into two groups treated with different acquisition and processing protocols.

Results: The overall sensitivity was as high as (169/176) 96% in both groups, while the specificity was higher in the group in which semi-quantitative evaluation of somatostatin receptor density was performed: (23/26) 88% vs (39/51) 76%. The use of this method is recommended to increase the specificity of 111In-pentetreotide imaging.

Conclusions: Our results with somatostatin receptor imaging in neuroendocrine tumours of the gastro-entero-pancreatic tract demonstrate that all figures of merit are excellent when imaging is accurately performed and analysed by experienced operators.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gastrointestinal Neoplasms / diagnostic imaging*
  • Humans
  • Indium Radioisotopes*
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / diagnostic imaging*
  • Pancreatic Neoplasms / diagnostic imaging*
  • Radiopharmaceuticals*
  • Receptors, Somatostatin / analysis*
  • Sensitivity and Specificity
  • Somatostatin / analogs & derivatives*
  • Tomography, Emission-Computed, Single-Photon


  • Indium Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Somatostatin
  • pentetreotide